<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515589</url>
  </required_header>
  <id_info>
    <org_study_id>20001</org_study_id>
    <nct_id>NCT04515589</nct_id>
  </id_info>
  <brief_title>Central Aspects of Pain in Rheumatoid Arthritis</brief_title>
  <acronym>CAP-RA</acronym>
  <official_title>Central Aspects of Pain in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Versus Arthritis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to measure the psychometric properties of a newly developed Central Aspects&#xD;
      of Pain in Rheumatoid Arthritis (CAP-RA) questionnaire, and investigate the ability of this&#xD;
      questionnaire to measure central mechanisms of pain and also to predict worse pain and&#xD;
      fatigue outcomes in people with Rheumatoid Arthritis (RA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent pain and fatigue are prevalent and disabling symptoms in people with Rheumatoid&#xD;
      Arthritis, even in the absence of active inflammation. The investigators believe that these&#xD;
      symptoms may be a result of abnormal pain processing by the Central Nervous System (CNS), in&#xD;
      a process called central sensitization.&#xD;
&#xD;
      The investigators have developed a short, self-report questionnaire to measure central pain&#xD;
      mechanisms in people with RA. It is called Central Aspects of Pain in Rheumatoid Arthritis&#xD;
      (CAP-RA), and was adapted from a pre-existing questionnaire called CAP-Knee (which measures&#xD;
      central sensitization in people with chronic knee pain).&#xD;
&#xD;
      This study aims to measure the psychometric properties of CAP-RA, and the ability of the&#xD;
      questionnaire to predict worse pain in the RA population. Secondary objectives of the study&#xD;
      include predicting worse fatigue in people with RA, deriving CAP-RA scoring recommendations,&#xD;
      investigating other factors associated with persistent RA pain, the association between&#xD;
      central sensitization and pain, and investigating the course of pain and fatigue in RA.&#xD;
&#xD;
      Participants will be recruited from a Rheumatology clinic. At baseline and 12 weeks these&#xD;
      participants will undergo quantitative sensory testing (QST, pain tests), ultrasound for&#xD;
      synovitis, clinical assessments, laboratory tests for systemic inflammation and, complete a&#xD;
      questionnaire booklet, including the CAP-RA questionnaire.&#xD;
&#xD;
      Some participants will complete the CAP-RA questionnaire 1 week after the baseline visit to&#xD;
      assess the test-retest reliability of the questionnaire.&#xD;
&#xD;
      In addition, participants will provide weekly pain and fatigue self-report via text message&#xD;
      (SMS) for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric properties of CAP-RA</measure>
    <time_frame>Baseline</time_frame>
    <description>A detailed assessment of the psychometric properties of CAP-RA. Higher scores indicate stronger central mechanisms of pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychometric properties of CAP-RA</measure>
    <time_frame>1 week test-retest</time_frame>
    <description>A detailed assessment of the psychometric properties of CAP-RA. Higher scores indicate stronger central mechanisms of pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bodily pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Numerical Rating Scale (0-10) of bodily pain - increasing severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative Sensory Testing</measure>
    <time_frame>Baseline</time_frame>
    <description>Validation of CAP-RA as a measure of central sensitization. Lower pressure pain detection thresholds indicate greater sensitivity to painful stimulation. Higher temporal summation indicates dysfunctional pain response. Higher conditioned pain modulation indicates more dysfunctional pain response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Sensory Testing</measure>
    <time_frame>12 weeks</time_frame>
    <description>Validation of CAP-RA as a measure of central sensitization. Lower pressure pain detection thresholds indicate greater sensitivity to painful stimulation. Higher temporal summation indicates dysfunctional pain response. Higher conditioned pain modulation indicates more dysfunctional pain response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>12 weeks</time_frame>
    <description>Bristol Rheumatoid Arthritis Multidimensional Fatigue Scale (BRAFS). 0-70 scale of increasing fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and trajectory of bodily pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Responses to mobile phone text messages giving 0-10 pain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and trajectory of fatigue</measure>
    <time_frame>12 weeks</time_frame>
    <description>Responses to mobile phone text messages giving 0-10 fatigue scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>International Physical Activity Questionnaire (IPAQ) -short form. Lower scores indicate less physical activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status</measure>
    <time_frame>12 weeks</time_frame>
    <description>Health Assessment Questionnaire (HAQ). Range 0-3 with higher scores indicating greater disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain mechanisms</measure>
    <time_frame>12 weeks</time_frame>
    <description>PainDETECT. Higher scores indicating greater neuropathic pain mechanisms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental health</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) - depression and anxiety. Higher scores indicating worse feelings of anxiety and lower mood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central sensitization</measure>
    <time_frame>12 weeks</time_frame>
    <description>Central Sensitisation Inventory 9 (CSI-9). Higher scores indicate greater central sensitisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint inflammation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Ultrasound assessment showing synovitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen joints</measure>
    <time_frame>12 weeks</time_frame>
    <description>Swollen joint count (0-28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation-Erythrocyte sedimentation rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Erythrocyte sedimentation rate (mm per hour)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation-CRP</measure>
    <time_frame>12 weeks</time_frame>
    <description>High sensitivity C-reactive protein</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Main study cohort</arm_group_label>
    <description>The main study cohort in this single-arm cohort is 250 adults with rheumatoid arthritis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include people with Rheumatoid Arthritis receiving care at the&#xD;
        Kings Mill Hospital, Sherwood Forest NHS Foundation Trust, Nottinghamshire, UK, who meet&#xD;
        the eligibility criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (age≥18y) of any sex and ethnicity.&#xD;
&#xD;
          -  Satisfy EULAR criteria for RA.&#xD;
&#xD;
          -  Active RA, as defined as DAS28 ≥3.2 at baseline visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give informed consent.&#xD;
&#xD;
          -  Insufficient understanding of spoken or written English to comply with the&#xD;
             requirements of the study protocol&#xD;
&#xD;
          -  Unable or unlikely to complete the proposed 12-week study follow up (eg. moving house,&#xD;
             terminal diagnosis, current or planned pregnancy).&#xD;
&#xD;
          -  Active comorbidity (e.g. uncontrolled diabetes mellitus, cancer, infection) requiring&#xD;
             changes in medical treatment at baseline&#xD;
&#xD;
          -  Major active psychiatric condition (e.g. major depression)&#xD;
&#xD;
          -  Inability to meet the requirements of clinical assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Walsh</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Onosi S Ifesemen</last_name>
    <phone>+441153231810</phone>
    <email>mbxosi@nottingham.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel F McWilliams</last_name>
    <phone>+441153231942</phone>
    <email>dan.mcwilliams@nottingham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sherwood Forest Hospitals NHS Foundation Trust</name>
      <address>
        <city>Mansfield</city>
        <state>Nottinghamshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Alison Steel</last_name>
    </contact>
    <investigator>
      <last_name>David A Walsh, FRCP PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Central Sensitization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Pre-planned analyses will be performed by the study team. Requests for collaborative analyses of IPD, using non-identifiable data, may be made to the study PI.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

